Operating Profit of 216.2 Billion KRW, Net Profit of 143.5 Billion KRW
Record-High Sales Surpass Previous Year's Performance
Hanmi Pharm achieved record-high performance last year with sales of 1.4955 trillion KRW, operating profit of 216.2 billion KRW, and net profit of 143.5 billion KRW.
Hanmi Pharm announced on the 4th that these sales, operating profit, and net profit figures were recorded as preliminary consolidated results for 2024. Sales increased by 4.6 billion KRW compared to the previous year, while operating profit and net profit decreased by 4.5 billion KRW and 21.9 billion KRW, respectively. The operating profit margin reached 14.5%, and 209.8 billion KRW, equivalent to 14.0% of sales, was invested in R&D.
In the fourth quarter of 2024, sales and operating profit were 351.6 billion KRW and 30.5 billion KRW, respectively, down 70.8 billion KRW and 39.6 billion KRW compared to the same period last year. A Hanmi Pharm official stated, "In the fourth quarter of last year, we were affected by uncontrollable factors such as the base effect from milestones inflow from MSD compared to the previous year, delayed influenza outbreaks, and prolonged conflicts between medical and government sectors, but the company achieved sustainable growth based on solid fundamentals."
Hanmi Pharm recorded the top spot in domestic outpatient prescription sales for seven consecutive years (based on UBIST) last year, showing a 7.1% growth rate in the outpatient prescription sector compared to the previous year. In particular, the dyslipidemia combination drug 'Rosuzet' alone achieved prescription sales of 210.3 billion KRW, a 17.6% increase compared to the same period last year, and the hypertension treatment combination product group 'AmozalTan Family' also posted sales of 146.7 billion KRW. Over the past year, the company released 20 'blockbuster' products with sales exceeding 10 billion KRW each, maintaining the record for the most among domestic pharmaceutical companies.
Hanmi Pharm’s local subsidiary in China, Beijing Hanmi Pharm, achieved cumulative sales of 385.6 billion KRW, operating profit of 82.2 billion KRW, and net profit of 74.2 billion KRW last year. Since surpassing annual sales of 300 billion KRW for the first time in 2022, Beijing Hanmi has maintained a steady trend for three consecutive years. However, in the fourth quarter of last year, sales temporarily slowed due to delayed respiratory disease outbreaks and the base effect of mycoplasma pneumonia in China.
Additionally, Hanmi Pharm announced that it is preparing for the relay launch of next-generation improved and combination drugs, spotlighted as 'Post-Rosuzet.' Throughout the past year, the company has also showcased R&D achievements by presenting 39 research results on innovative drugs in oncology, obesity metabolism, and rare diseases at numerous global conferences.
Park Jae-hyun, CEO of Hanmi Pharm, said, "This year, we will promptly pursue management stabilization to realize innovation and leap forward in all business areas. We will vigorously advance to become a global healthcare market-leading R&D-centered pharmaceutical and bio company, further enhancing corporate value to meet the expectations and support of our shareholders."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
